Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals plc is an innovative biopharmaceutical company founded in 2003 and headquartered in Dublin, Ireland. Led by CEO Bruce Cozadd, Jazz is dedicated to developing and commercializing life-changing medicines, focusing primarily on neuroscience and sleep disorders, oncology, and hematology. The company is particularly well-known for its narcolepsy treatments, including Xyrem and Xywav. Jazz Pharmaceuticals has steadily grown its portfolio through strategic acquisitions and robust research and development efforts. In recent years, the company has reported annual revenues in the billions, reflecting its significant impact and presence in the global biopharmaceutical market. Jazz continues to drive forward its mission by investing in novel therapies that address unmet medical needs and improve patient outcomes.